Galectin Therapeutics Toekomstige groei
Future criteriumcontroles 5/6
Galectin Therapeutics is forecast to grow earnings and revenue by 59.9% and 66.6% per annum respectively while EPS is expected to grow by 52.3% per annum.
Belangrijke informatie
59.9%
Groei van de winst
52.3%
Groei van de winst per aandeel
| Biotechs winstgroei | 27.1% |
| Inkomstengroei | 66.6% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 16 Aug 2024 |
Recente toekomstige groei-updates
Recent updates
Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer
Oct 12Galectin Therapeutics GAAP EPS of -$0.16
Aug 15Galectin: Ability To Potentially Target Unmet Medical Need
Jul 11Galectin: Pursuing A Subset In The NASH Space
Jul 01Read This Before Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Shares
Feb 25
Is Galectin Therapeutics (NASDAQ:GALT) In A Good Position To Deliver On Growth Plans?
Jan 21How Much Of Galectin Therapeutics, Inc. (NASDAQ:GALT) Do Insiders Own?
Dec 09Galectin Therapeutics reports Q3 results
Nov 09Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 180 | -69 | N/A | N/A | 1 |
| 12/31/2025 | 36 | -105 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -49 | N/A | N/A | 1 |
| 6/30/2024 | N/A | -48 | -33 | -33 | N/A |
| 3/31/2024 | N/A | -45 | -34 | -34 | N/A |
| 12/31/2023 | N/A | -45 | -33 | -33 | N/A |
| 9/30/2023 | N/A | -45 | -36 | -36 | N/A |
| 6/30/2023 | N/A | -40 | -36 | -36 | N/A |
| 3/31/2023 | N/A | -40 | -34 | -34 | N/A |
| 12/31/2022 | N/A | -39 | -31 | -31 | N/A |
| 9/30/2022 | N/A | -35 | -31 | -31 | N/A |
| 6/30/2022 | N/A | -35 | -27 | -27 | N/A |
| 3/31/2022 | N/A | -34 | -26 | -26 | N/A |
| 12/31/2021 | N/A | -31 | -24 | -24 | N/A |
| 9/30/2021 | N/A | -31 | -23 | -23 | N/A |
| 6/30/2021 | N/A | -29 | -26 | -26 | N/A |
| 3/31/2021 | N/A | -26 | -23 | -23 | N/A |
| 12/31/2020 | N/A | -24 | -21 | -21 | N/A |
| 9/30/2020 | N/A | -21 | -19 | -19 | N/A |
| 6/30/2020 | N/A | -18 | -12 | -12 | N/A |
| 3/31/2020 | N/A | -15 | -12 | -12 | N/A |
| 12/31/2019 | N/A | -20 | -11 | -11 | N/A |
| 9/30/2019 | N/A | -18 | -9 | -9 | N/A |
| 6/30/2019 | N/A | -19 | -9 | -9 | N/A |
| 3/31/2019 | N/A | -20 | -10 | -10 | N/A |
| 12/31/2018 | N/A | -15 | -10 | -10 | N/A |
| 9/30/2018 | N/A | -14 | -12 | -12 | N/A |
| 6/30/2018 | N/A | -16 | -14 | -14 | N/A |
| 3/31/2018 | N/A | -17 | N/A | -16 | N/A |
| 12/31/2017 | N/A | -17 | N/A | -16 | N/A |
| 9/30/2017 | N/A | -20 | N/A | -17 | N/A |
| 6/30/2017 | N/A | -20 | N/A | -17 | N/A |
| 3/31/2017 | N/A | -21 | N/A | -17 | N/A |
| 12/31/2016 | N/A | -22 | N/A | -16 | N/A |
| 9/30/2016 | N/A | -22 | N/A | -16 | N/A |
| 6/30/2016 | N/A | -24 | N/A | -18 | N/A |
| 3/31/2016 | N/A | -23 | N/A | -16 | N/A |
| 12/31/2015 | N/A | -21 | N/A | -17 | N/A |
| 9/30/2015 | N/A | -20 | N/A | -15 | N/A |
| 6/30/2015 | N/A | -18 | N/A | -14 | N/A |
| 3/31/2015 | N/A | -17 | N/A | -13 | N/A |
| 12/31/2014 | N/A | -17 | N/A | -12 | N/A |
| 9/30/2014 | N/A | -16 | N/A | -11 | N/A |
| 6/30/2014 | N/A | -16 | N/A | -9 | N/A |
| 3/31/2014 | N/A | -24 | N/A | -9 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: GALT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Winst versus markt: GALT is forecast to become profitable over the next 3 years, which is considered above average market growth.
Hoge groeiwinsten: GALT is expected to become profitable in the next 3 years.
Omzet versus markt: GALT's revenue (66.6% per year) is forecast to grow faster than the US market (8.9% per year).
Hoge groei-inkomsten: GALT's revenue (66.6% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if GALT's Return on Equity is forecast to be high in 3 years time